2025 Q3 -tulosraportti
99 päivää sitten1 t 51 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
6 865
Myynti
Määrä
5 281
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 83 | - | - | ||
| 121 | - | - | ||
| 529 | - | - | ||
| 152 | - | - | ||
| 165 | - | - |
Ylin
30,85VWAP
Alin
29,55VaihtoMäärä
1 33 240
VWAP
Ylin
30,85Alin
29,55VaihtoMäärä
1 33 240
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 23.10.2025 | |
| 2025 Q2 -tulosraportti | 16.7.2025 | |
| 2025 Q1 -tulosraportti | 6.5.2025 | |
| 2024 Q4 -tulosraportti | 6.2.2025 | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·23.1.A little research and now the excitement is rising. Morgan Stanley's holdings confirm that they largely act through financial instruments. Here are the details from the flagging:*** It is Morgan Stanley & Co. International plc (based in London) that stands as the holder. This is the bank's main unit for international trading and investment banking, which is the typical unit when they act on behalf of clients or manage large derivative positions. MS acts as a proxy for an owner, my belief is Novo and they are preparing for a bid, alternatively someone else who is just waiting for a bigger deal in the company. There will be continued purchases soon, bigger events, I am considering to increase holdings further.- ·23.1.Acquisition ? Morgan Stanley bought 5% and still no info on who the owner is. I can't help but speculate about this. Novo Holding (Novo A/S) currently owns approx. 26% of the shares and 27% of the votes. At 30% ownership, a mandatory bid obligation arises and a very strong position for acquisition. Could it be that MS is acting as an intermediary before Novo wants to take a bid position? Novo Holdings is one of the world's most active investors in Life Science and regularly buys significantly larger companies than Orexo. Their cash is enormous and Amorph would fit perfectly within their pharmaceutical and development portfolio. Why would they want to release this unique platform to competitors when they can buy it cheaply now. I believe in a bid of 60-80kr, then everything drug-related remaining within US pharma will be sold, after which Novo will develop the pipeline with Amorph. For us shareholders, I think it will be accepted even if the value in the company over time is much greater and I would rather see that an acquisition does not come now, but that the company's true values have time to develop in the coming years. We'll see, but as I said, hold on to your shares.
·16.1.Hi everyone. Does anyone here know why it's going down a bit right now.
·7.1.I wonder if Morgan Stanley forgot about the low-voting C-shares when they were forced to disclose 5.19 % of the votes? But now they have bought more, as they also disclose over 5 % of the shares. Nice that something finally seems to be happening. Good with double disclosure!- ·5.1.Stakeholders Orexo's holdings: Emergent BioSolutions sells narcan and Kloxxado today, the latter a liquid-based spray that is a competitor to Izipry in the USA. EBS sells these two products for several billions annually and has a sales network and well-developed distribution. That Orexo is now coming with Izypry, OX 125, and OX390, which is backed by BARDA, naturally constitutes a direct problem for EBS. Orexo's products are better in so many aspects that they will take market shares in this large market in the USA but also outside the USA. Orexo has now opened up for another player to take this over, as they have left their sales organization for zubsolv in the USA and are no longer interested in selling in this market themselves. There is now only one way for Orexo here. Sell to another large player. For EBS, this now constitutes an even bigger problem, as a larger player than Orexo with the muscle to sell in the USA market can step in. In other words, the price is now rising on what OREXO has within US inc, it is likely why we see Morgan Stanley coming in now and building holdings and there will be more. Regarding the Amorph platform and OX640, there are completely different large pharmaceutical players who can come in - Pfizer, Novo, Viatrisi, Elli Lilly, Decxel and more, of course. We are heading towards a really exciting 2026 for Orexo.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
99 päivää sitten1 t 51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·23.1.A little research and now the excitement is rising. Morgan Stanley's holdings confirm that they largely act through financial instruments. Here are the details from the flagging:*** It is Morgan Stanley & Co. International plc (based in London) that stands as the holder. This is the bank's main unit for international trading and investment banking, which is the typical unit when they act on behalf of clients or manage large derivative positions. MS acts as a proxy for an owner, my belief is Novo and they are preparing for a bid, alternatively someone else who is just waiting for a bigger deal in the company. There will be continued purchases soon, bigger events, I am considering to increase holdings further.
- ·23.1.Acquisition ? Morgan Stanley bought 5% and still no info on who the owner is. I can't help but speculate about this. Novo Holding (Novo A/S) currently owns approx. 26% of the shares and 27% of the votes. At 30% ownership, a mandatory bid obligation arises and a very strong position for acquisition. Could it be that MS is acting as an intermediary before Novo wants to take a bid position? Novo Holdings is one of the world's most active investors in Life Science and regularly buys significantly larger companies than Orexo. Their cash is enormous and Amorph would fit perfectly within their pharmaceutical and development portfolio. Why would they want to release this unique platform to competitors when they can buy it cheaply now. I believe in a bid of 60-80kr, then everything drug-related remaining within US pharma will be sold, after which Novo will develop the pipeline with Amorph. For us shareholders, I think it will be accepted even if the value in the company over time is much greater and I would rather see that an acquisition does not come now, but that the company's true values have time to develop in the coming years. We'll see, but as I said, hold on to your shares.
- ·16.1.Hi everyone. Does anyone here know why it's going down a bit right now.
- ·7.1.I wonder if Morgan Stanley forgot about the low-voting C-shares when they were forced to disclose 5.19 % of the votes? But now they have bought more, as they also disclose over 5 % of the shares. Nice that something finally seems to be happening. Good with double disclosure!
- ·5.1.Stakeholders Orexo's holdings: Emergent BioSolutions sells narcan and Kloxxado today, the latter a liquid-based spray that is a competitor to Izipry in the USA. EBS sells these two products for several billions annually and has a sales network and well-developed distribution. That Orexo is now coming with Izypry, OX 125, and OX390, which is backed by BARDA, naturally constitutes a direct problem for EBS. Orexo's products are better in so many aspects that they will take market shares in this large market in the USA but also outside the USA. Orexo has now opened up for another player to take this over, as they have left their sales organization for zubsolv in the USA and are no longer interested in selling in this market themselves. There is now only one way for Orexo here. Sell to another large player. For EBS, this now constitutes an even bigger problem, as a larger player than Orexo with the muscle to sell in the USA market can step in. In other words, the price is now rising on what OREXO has within US inc, it is likely why we see Morgan Stanley coming in now and building holdings and there will be more. Regarding the Amorph platform and OX640, there are completely different large pharmaceutical players who can come in - Pfizer, Novo, Viatrisi, Elli Lilly, Decxel and more, of course. We are heading towards a really exciting 2026 for Orexo.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
6 865
Myynti
Määrä
5 281
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 83 | - | - | ||
| 121 | - | - | ||
| 529 | - | - | ||
| 152 | - | - | ||
| 165 | - | - |
Ylin
30,85VWAP
Alin
29,55VaihtoMäärä
1 33 240
VWAP
Ylin
30,85Alin
29,55VaihtoMäärä
1 33 240
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 23.10.2025 | |
| 2025 Q2 -tulosraportti | 16.7.2025 | |
| 2025 Q1 -tulosraportti | 6.5.2025 | |
| 2024 Q4 -tulosraportti | 6.2.2025 | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
2025 Q3 -tulosraportti
99 päivää sitten1 t 51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 23.10.2025 | |
| 2025 Q2 -tulosraportti | 16.7.2025 | |
| 2025 Q1 -tulosraportti | 6.5.2025 | |
| 2024 Q4 -tulosraportti | 6.2.2025 | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·23.1.A little research and now the excitement is rising. Morgan Stanley's holdings confirm that they largely act through financial instruments. Here are the details from the flagging:*** It is Morgan Stanley & Co. International plc (based in London) that stands as the holder. This is the bank's main unit for international trading and investment banking, which is the typical unit when they act on behalf of clients or manage large derivative positions. MS acts as a proxy for an owner, my belief is Novo and they are preparing for a bid, alternatively someone else who is just waiting for a bigger deal in the company. There will be continued purchases soon, bigger events, I am considering to increase holdings further.
- ·23.1.Acquisition ? Morgan Stanley bought 5% and still no info on who the owner is. I can't help but speculate about this. Novo Holding (Novo A/S) currently owns approx. 26% of the shares and 27% of the votes. At 30% ownership, a mandatory bid obligation arises and a very strong position for acquisition. Could it be that MS is acting as an intermediary before Novo wants to take a bid position? Novo Holdings is one of the world's most active investors in Life Science and regularly buys significantly larger companies than Orexo. Their cash is enormous and Amorph would fit perfectly within their pharmaceutical and development portfolio. Why would they want to release this unique platform to competitors when they can buy it cheaply now. I believe in a bid of 60-80kr, then everything drug-related remaining within US pharma will be sold, after which Novo will develop the pipeline with Amorph. For us shareholders, I think it will be accepted even if the value in the company over time is much greater and I would rather see that an acquisition does not come now, but that the company's true values have time to develop in the coming years. We'll see, but as I said, hold on to your shares.
- ·16.1.Hi everyone. Does anyone here know why it's going down a bit right now.
- ·7.1.I wonder if Morgan Stanley forgot about the low-voting C-shares when they were forced to disclose 5.19 % of the votes? But now they have bought more, as they also disclose over 5 % of the shares. Nice that something finally seems to be happening. Good with double disclosure!
- ·5.1.Stakeholders Orexo's holdings: Emergent BioSolutions sells narcan and Kloxxado today, the latter a liquid-based spray that is a competitor to Izipry in the USA. EBS sells these two products for several billions annually and has a sales network and well-developed distribution. That Orexo is now coming with Izypry, OX 125, and OX390, which is backed by BARDA, naturally constitutes a direct problem for EBS. Orexo's products are better in so many aspects that they will take market shares in this large market in the USA but also outside the USA. Orexo has now opened up for another player to take this over, as they have left their sales organization for zubsolv in the USA and are no longer interested in selling in this market themselves. There is now only one way for Orexo here. Sell to another large player. For EBS, this now constitutes an even bigger problem, as a larger player than Orexo with the muscle to sell in the USA market can step in. In other words, the price is now rising on what OREXO has within US inc, it is likely why we see Morgan Stanley coming in now and building holdings and there will be more. Regarding the Amorph platform and OX640, there are completely different large pharmaceutical players who can come in - Pfizer, Novo, Viatrisi, Elli Lilly, Decxel and more, of course. We are heading towards a really exciting 2026 for Orexo.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
6 865
Myynti
Määrä
5 281
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 83 | - | - | ||
| 121 | - | - | ||
| 529 | - | - | ||
| 152 | - | - | ||
| 165 | - | - |
Ylin
30,85VWAP
Alin
29,55VaihtoMäärä
1 33 240
VWAP
Ylin
30,85Alin
29,55VaihtoMäärä
1 33 240
Välittäjätilasto
Dataa ei löytynyt